Zeit	Aktuelle Nachrichten Sprache: Alle DE EN	Leser	Medien
Sa	Eli Lilly and Company: Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRa-targeting ADC at ESMO 2026	1.686	PR Newswire	Sofetabart mipitecan (Sofe-M) in combination with bevacizumab demonstrated a 79% confirmed objective response rate and 100% disease control rate, with similar activity... ► Artikel lesen
Sa	Orion Oyj: Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence	787	GlobeNewswire (Europe)	ORION CORPORATION PRESS RELEASE 24 OCTOBER 2026 at 9.35 EEST Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk... ► Artikel lesen
Sa	Novartis feiert MS-Daten, Eli Lilly zahlt bis zu 3,8 Milliarden Dollar für Psychedelika: Worin Big Pharma investiert		Small- & Micro Cap Investment
Sa	AbbVie Gains FDA Approval For Subcutaneous Induction Of SKYRIZI In Crohn's Disease	647	AFX News	WASHINGTON (dpa-AFX) - AbbVie (ABBV) announced that the U.S. Food and Drug Administration approved a subcutaneous induction regimen for SKYRIZI (risankizumab-rzaa) for adults with moderately... ► Artikel lesen
Sa	BioInvent International: BioInvent's BI-1808 and KEYTRUDA Induce Durable Responses in Heavily Pretreated Platinum-Resistant Ovarian Cancer	583	ACCESS Newswire	BioInvent International (STO:BINV) - Updated efficacy data in 34 evaluable patients with a chemotherapy-free regimen; randomized Part C will add BI-1808 to the new standard of care24% objective response... ► Artikel lesen
Sa	AstraZeneca: Perioperative IMFINZI (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer	482	Business Wire	More than three quarters of patients were still alive two years after treatment with perioperative IMFINZI plus three cycles of EV given before surgery Data demonstrated statistically significant... ► Artikel lesen
Sa	Roche Reports Positive Phase III Data For Investigational IgAN Therapy Sefaxersen	479	AFX News	SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RHHBY) announced new late-breaking data from the ongoing Phase III IMAgINATION study showing that its investigational therapy sefaxersen delivered a statistically... ► Artikel lesen
Sa	Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer	471	Business Wire	Phase 1/2 study will evaluate INCB161734 plus petosemtamab and standard-of-care chemotherapy in first-line KRAS G12D-mutated metastatic colorectal cancer (mCRC) Incyte (Nasdaq:INCY) and Genmab... ► Artikel lesen
Sa	Genmab A/S: Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer	447	Business Wire	Phase 1/2 study will evaluate petosemtamab plus INCB161734 and standard-of-care chemotherapy in first-line KRAS G12D-mutated metastatic colorectal cancer (mCRC) Genmab A/S (Nasdaq: GMAB) and... ► Artikel lesen
Sa	Genmab, Incyte Partner On Trial Of Petosemtamab Combination In KRAS G12D-Mutated Colorectal Cancer	361	AFX News	WASHINGTON (dpa-AFX) - Genmab A/S (GMAB) and Incyte (INCY) have entered into a clinical trial collaboration to evaluate a novel combination therapy for patients with metastatic colorectal cancer... ► Artikel lesen

Unternehmen / Aktien	Kurs	Dividende 12M	Div.-Rendite	Erw. Dividende
MPH HEALTH CARE	28,100	10,00	+35,59 %	1,01
KRKA	252,00	48,48	+19,24 %	48,06
SANOFI SA ADR	36,800	4,12	+11,20 %	1,90
BOIRON	17,500	1,35	+7,71 %	1,20
SANOFI	74,36	4,12	+5,54 %	4,26
CSPC PHARMA	0,943	0,05	+5,37 %	0,02
FINE FOODS & PHARMACEUTICALS NTM	6,180	0,32	+5,18 %	0,16
FAES FARMA	4,650	0,23	+4,98 %	0,08
COSMO	57,90	2,10	+3,63 %
PHARMANUTRA	70,20	2,40	+3,42 %	1,26

1 2 3 4 5 Weiter >>

15.10.

Dividendenbekanntmachungen (15.10.2026)

Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABBOTT LABORATORIES US0028241000 0,63 USD 0,5648 EUR ABBOTT LABORATORIES CDR CA0028221046 0,1096 CAD 0,069 EUR ABBVIE INC US00287Y1091 1,73 USD 1,5512 EUR ABBVIE INC CDR CA00288K1084 0...
► Artikel lesen

Aktien im Artikel:

14.10.

Dividendenbekanntmachungen (14.10.2026)

Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACADEMY SPORTS AND OUTDOORS INC US00402L1070 0,15 USD EUR AECOM US00766T1007 0,31 USD 0,2768 EUR AGREE REALTY CORPORATION US0084921008 0,267 USD EUR AMERIGO RESOURCES LTD CA03074G1090 0...
► Artikel lesen

Aktien im Artikel:

Dividendenbekanntmachungen (23.10.2026)

Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADVANCE AUTO PARTS INC US00751Y1064 0,25 USD EUR ALPHAMIN RESOURCES CORP MU0456S00006 0,13 CAD 0,0827 EUR AMERICAN FINANCIAL GROUP INC US0259321042 0,97 USD EUR ARB CORPORATION...
► Artikel lesen

Aktien im Artikel:

XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 19.10.2026

Folgende Wertpapiere werden in den Handel an der Frankfurter Wertpapierbörse (FWB) aufgenommen. 1. US88025U1097 10X GENOMICS INC 2. NL0000852564 AALBERTS NV 3. SE0016589188 ELECTROLUX AB 4. SE0000115446 VOLVO AB B 5. CH0329023102 AC IMMUNE...
► Artikel lesen

Aktien im Artikel:

Dividendenbekanntmachungen (19.10.2026)

Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADENTRA INC CA00686A1084 0,16 CAD 0,1007 EUR ANADOLU EFES BIRACILIK VE MALT SANAYII A ... US0325232017 0,0036 USD EUR ANADOLU EFES BIRACILIK VE MALT SANAYII A ... US0325232017 0...
► Artikel lesen

Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.

Pharma

Gewinner und Verlierer in der Branche Pharma

Top-News in der Branche Pharma

Aktien nach Dividendenrendite in der Branche Pharma

Bestbewertete Nachrichten in der Branche Pharma